SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of their patent application in South Korea for a novel cocaine addiction treatment. The therapy combines Clearmind's MEAI (5-methoxy-2-aminoindane) with SciSparc's PEA (Palmitoylethanolamide).
The patent application is supported by promising preclinical trial results from Bar-Ilan University's Gonda Multidisciplinary Brain Research Center. The research demonstrated that MEAI significantly reduced cocaine-induced craving in animal subjects without affecting their natural reward responses, such as sucrose seeking behavior. This suggests the treatment specifically targets drug-related compulsions while preserving normal reward mechanisms.
This South Korean patent application adds to the companies' existing intellectual property portfolio, which includes multiple applications filed in the United States and other global territories.
SciSparc (Nasdaq: SPRC) e Clearmind Medicine hanno raggiunto un traguardo significativo con la pubblicazione della loro domanda di brevetto in Corea del Sud per un nuovo trattamento della dipendenza da cocaina. La terapia combina il MEAI (5-metossi-2-aminoindano) di Clearmind con il PEA (Palmitoiletanolamide) di SciSparc.
La domanda di brevetto è supportata da promettenti risultati di studi preclinici del Gonda Multidisciplinary Brain Research Center dell'Università Bar-Ilan. La ricerca ha dimostrato che il MEAI riduce significativamente il desiderio indotto dalla cocaina nei soggetti animali senza influenzare le loro risposte naturali di ricompensa, come il comportamento di ricerca del saccarosio. Ciò suggerisce che il trattamento si concentra specificamente sulle compulsioni legate alla droga, preservando i normali meccanismi di ricompensa.
Questa domanda di brevetto in Corea del Sud si aggiunge al portafoglio di proprietà intellettuale esistente delle aziende, che include diverse domande presentate negli Stati Uniti e in altri territori globali.
SciSparc (Nasdaq: SPRC) y Clearmind Medicine han alcanzado un hito significativo con la publicación de su solicitud de patente en Corea del Sur para un nuevo tratamiento de la adicción a la cocaína. La terapia combina el MEAI (5-metoxi-2-aminoindano) de Clearmind con el PEA (Palmitoiletanolamida) de SciSparc.
La solicitud de patente está respaldada por prometedores resultados de ensayos preclínicos del Gonda Multidisciplinary Brain Research Center de la Universidad Bar-Ilan. La investigación demostró que el MEAI redujo significativamente el deseo inducido por la cocaína en sujetos animales sin afectar sus respuestas naturales de recompensa, como el comportamiento de búsqueda de sacarosa. Esto sugiere que el tratamiento se dirige específicamente a las compulsiones relacionadas con las drogas, preservando los mecanismos de recompensa normales.
Esta solicitud de patente en Corea del Sur se suma al portafolio de propiedad intelectual existente de las empresas, que incluye múltiples solicitudes presentadas en los Estados Unidos y en otros territorios globales.
SciSparc (Nasdaq: SPRC)와 Clearmind Medicine은 한국에서 새로운 코카인 중독 치료법에 대한 특허 출원을 발표하며 중요한 이정표를 세웠습니다. 이 치료법은 Clearmind의 MEAI(5-메톡시-2-아미노인단)와 SciSparc의 PEA(팔미토일에탄올아미드)를 결합합니다.
특허 출원은 바르일란 대학교의 곤다 다학제 뇌 연구 센터에서의 유망한 전임상 시험 결과에 의해 뒷받침됩니다. 연구 결과, MEAI는 동물 실험에서 코카인으로 유도된 갈망을 상당히 줄였으며, 자연적인 보상 반응(예: 설탕 탐색 행동)에는 영향을 미치지 않았습니다. 이는 치료가 약물 관련 강박 행동을 특정적으로 겨냥하면서 정상적인 보상 메커니즘을 보존한다는 것을 시사합니다.
이 한국의 특허 출원은 미국 및 기타 글로벌 지역에 제출된 여러 출원을 포함하는 회사의 기존 지적 재산 포트폴리오에 추가됩니다.
SciSparc (Nasdaq: SPRC) et Clearmind Medicine ont atteint une étape importante avec la publication de leur demande de brevet en Corée du Sud pour un nouveau traitement de la dépendance à la cocaïne. La thérapie combine le MEAI (5-méthoxy-2-aminoindane) de Clearmind avec le PEA (Palmitoïléthanolamide) de SciSparc.
La demande de brevet est soutenue par des résultats prometteurs d'essais précliniques du Gonda Multidisciplinary Brain Research Center de l'Université Bar-Ilan. La recherche a démontré que le MEAI réduisait significativement le désir induit par la cocaïne chez les sujets animaux sans affecter leurs réponses naturelles de récompense, telles que le comportement de recherche de saccharose. Cela suggère que le traitement cible spécifiquement les compulsions liées aux drogues tout en préservant les mécanismes de récompense normaux.
Cette demande de brevet en Corée du Sud s'ajoute au portefeuille de propriété intellectuelle existant des entreprises, qui comprend plusieurs demandes déposées aux États-Unis et dans d'autres territoires mondiaux.
SciSparc (Nasdaq: SPRC) und Clearmind Medicine haben einen bedeutenden Meilenstein mit der Veröffentlichung ihres Patentantrags in Südkorea für eine neuartige Behandlung von Kokainabhängigkeit erreicht. Die Therapie kombiniert Clearminds MEAI (5-Methoxy-2-Aminoindan) mit SciSparcs PEA (Palmitoylethanolamid).
Der Patentantrag wird durch vielversprechende Ergebnisse aus präklinischen Studien des Gonda Multidisciplinary Brain Research Center der Bar-Ilan-Universität unterstützt. Die Forschung zeigte, dass MEAI das durch Kokain induzierte Verlangen bei Versuchstieren signifikant reduzierte, ohne ihre natürlichen Belohnungsreaktionen, wie das Verhalten bei der Suche nach Saccharose, zu beeinflussen. Dies deutet darauf hin, dass die Behandlung gezielt auf drogenbedingte Zwänge abzielt, während die normalen Belohnungsmechanismen erhalten bleiben.
Dieser Patentantrag in Südkorea erweitert das bestehende Portfolio an geistigem Eigentum der Unternehmen, das mehrere Anträge in den Vereinigten Staaten und anderen globalen Gebieten umfasst.
- Successful preclinical trial results showing reduced cocaine-seeking behavior
- Strategic patent application expansion into South Korean market
- Treatment specifically targets drug addiction without affecting natural reward mechanisms
- Still in preclinical stage, requiring extensive further testing
- No human trial data available yet
TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office (“KIPO”). The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide (“PEA”) for the treatment of cocaine addiction.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These results followed an earlier experiment in which animals treated with MEAI exhibited a significant reduction in cocaine-induced craving.
Building on these findings, further research assessed whether MEAI’s effect on drug-seeking behavior extends to natural rewards, as reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards, such as sucrose. This suggests that MEAI’s effect on drug craving is not linked to the general reward system but rather specifically targets drug-related compulsions.
This latest publication adds to multiple patent applications already filed in the U.S. and other global territories as part of the ongoing SciSparc-Clearmind collaboration.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of MEAI’s effect on drug craving. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What are the key findings of SciSparc's (SPRC) cocaine addiction treatment trials?
What compounds are used in SciSparc's (SPRC) new cocaine addiction treatment?
Where has SciSparc (SPRC) filed patent applications for its cocaine addiction treatment?
Who conducted the research for SciSparc's (SPRC) cocaine addiction treatment?
